Cargando…

Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy controls: a two year follow-up study

BACKGROUND: α-Synuclein has been proposed as a potential biomarker for Alzheimer’s disease (AD) and amnestic mild cognitive impairment (aMCI). However, results from α-synuclein measurements in cerebrospinal fluid (CSF) have been inconclusive, and to our knowledge, longitudinal studies of changes pri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berge, Guro, Sando, Sigrid B., Albrektsen, Grethe, Lauridsen, Camilla, Møller, Ina, Grøntvedt, Gøril R., Bråthen, Geir, White, Linda R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031325/ https://www.ncbi.nlm.nih.gov/pubmed/27653987 http://dx.doi.org/10.1186/s12883-016-0706-0

Ejemplares similares

Cerebrospinal Fluid Levels of Amyloid Beta 1–43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer’s Disease: A 2-Year Follow-Up Study
por: Lauridsen, Camilla, et al.
Publicado: (2016)

Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer’s Disease, But Has Similar Diagnostic Accuracy to Aβ42
por: Lauridsen, Camilla, et al.
Publicado: (2017)

The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease
por: Twohig, Daniel, et al.
Publicado: (2018)

The Amyloid, Tau, and Neurodegeneration (A/T/N) Classification Applied to a Clinical Research Cohort with Long-Term Follow-Up
por: Grøntvedt, Gøril Rolfseng, et al.
Publicado: (2020)

Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer’s disease
por: Giannisis, Andreas, et al.
Publicado: (2022)

Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease
por: Patra, Kalicharan, et al.
Publicado: (2018)

Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer’s Disease
por: Almdahl, Ina S., et al.
Publicado: (2017)

Association of Klotho Protein Levels and KL-VS Heterozygosity With Alzheimer Disease and Amyloid and Tau Burden
por: Grøntvedt, Gøril Rolfseng, et al.
Publicado: (2022)

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Associations of sleep characteristics with alpha‐synuclein in cerebrospinal fluid in older adults
por: Wang, Xiao‐Tong, et al.
Publicado: (2020)

Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies
por: Poggiolini, Ilaria, et al.
Publicado: (2021)

Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders
por: Agnello, Luisa, et al.
Publicado: (2022)

AlphaLISA detection of alpha-synuclein in the cerebrospinal fluid and its potential application in Parkinson’s disease diagnosis
por: Zhao, Hongli, et al.
Publicado: (2017)

Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies
por: Perra, Daniela, et al.
Publicado: (2021)

Incidence of Young Onset Dementia in Central Norway: A Population-Based Study
por: Kvello-Alme, Marte, et al.
Publicado: (2020)

The Prevalence and Subtypes of Young Onset Dementia in Central Norway: A Population-Based Study
por: Kvello-Alme, Marte, et al.
Publicado: (2019)

Time to Diagnosis in Young Onset Alzheimer’s Disease: A Population-Based Study from Central Norway
por: Kvello-Alme, Marte, et al.
Publicado: (2021)

Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay
por: Cariulo, Cristina, et al.
Publicado: (2019)

Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson’s Disease
por: Menéndez-González, Manuel, et al.
Publicado: (2018)

Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer’s Disease in Clinical Practice
por: Lilamand, Matthieu, et al.
Publicado: (2022)

In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion
por: Hessen, Erik, et al.
Publicado: (2019)

Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders
por: Constantinides, Vasilios C., et al.
Publicado: (2021)

α‐Synuclein RT‐QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies
por: Bongianni, Matilde, et al.
Publicado: (2019)

Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid
por: Kakuda, Keita, et al.
Publicado: (2019)

Apolipoprotein E ε2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort
por: Berge, Guro, et al.
Publicado: (2014)

Cerebrospinal Fluid Amyloid β(1-42), Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson’s Disease
por: Kang, Ju-Hee
Publicado: (2016)

Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels
por: Ibanez, Laura, et al.
Publicado: (2017)

Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease
por: Dolatshahi, Mahsa, et al.
Publicado: (2018)

Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study
por: Unterberger, Ursula, et al.
Publicado: (2014)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)

α‐Synuclein real‐time quaking‐induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism
por: van Rumund, Anouke, et al.
Publicado: (2019)

Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer’s disease and dementia with Lewy bodies from the prodromal stage
por: Bousiges, Olivier, et al.
Publicado: (2020)

Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders
por: Li, Jie-Qiong, et al.
Publicado: (2020)

Cerebrospinal fluid α synuclein concentrations in patients with positive AD biomarkers and extrapyramidal symptoms
por: Winkel, Izabela, et al.
Publicado: (2021)

Toxicity of extracellular alpha-synuclein is independent of intracellular alpha-synuclein
por: Dening, Yanina, et al.
Publicado: (2022)

Altered glymphatic enhancement of cerebrospinal fluid tracer in individuals with chronic poor sleep quality
por: Eide, Per Kristian, et al.
Publicado: (2022)

Increased alpha-synuclein tear fluid levels in patients with Parkinson’s disease
por: Maass, Fabian, et al.
Publicado: (2020)

Cerebrospinal fluid tracer efflux to parasagittal dura in humans
por: Ringstad, Geir, et al.
Publicado: (2020)

Passive Immunization in Alpha-Synuclein Preclinical Animal Models
por: Folke, Jonas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5dqcmsdpo3v2jsc9g082tk7kc5